Ian Frew
Principal Investigator
Department of Hematology, Oncology and Stem-Cell Transplantation
Medical Center University of Freiburg
Breisacher Str. 115
79106 Freiburg
- +49 761 270-71831
- ian.frew@uniklinik-freiburg.de
- Homepage
Current position
Academic training
| 1994 - 1997 | Bachelor of Science, Honours (Molecular Biology and Biochemistry), Australian National University, Canberra, Australia |
Advanced academic qualifications
| 2003 | PhD, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia |
Postgraduate positions
| Since 2017 | Full Professor (W3), Medical Center University of Freiburg |
| 2010 - 2016 | Assistant Professorship of the Swiss National Science Foundation |
| 2010 - 2016 | Assistant Professorship of the Zurich Center for Integrative Human Physiology, Institute of Physiology, University of Zurich, Zurich, Switzerland |
| 2003 - 2009 | Postdoctoral research fellow, Institute of Cell Biology, Swiss Federal Institute of Technology (ETH Zurich), Zurich, Switzerland |
| 1998 - 2003 | PhD, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia |
Miscellaneous (Honors, Awards)
| 2010 - 2016 | Swiss National Science Foundation Professorship |
| 2010 - 2015 | European Research Council Starting Grant |
| 2003 - 2005 | Serono Foundation for the Advancement of Medical Science Postdoctoral Fellowship in Cancer Biology |
| 2003 | Peter MacCallum Cancer Centre Postgraduate Research Medal |
| 1998 - 2002 | Sir Russell Grimwade PhD scholarship, University of Melbourne |
| 1997 | University Medal in Biochemistry and Molecular Biology, Australian National University |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Mohl DA, Lagies S, Zodel K, Zumkeller M, Peighambari A, Ganner A, Plattner DA, Neumann-Haefelin E, Adlesic M, Frew IJ, Kammerer B. Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma. Cells. 2023 Apr 7;12(8):1102. doi: 10.3390/cells12081102.
Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, Federkiel Y, Huang H, Hoefflin R, Adlesic M, Witt C, Hoffmann DJ, Metzger P, Lindemann RK, Zenke FT, Schell C, Boerries M, von Elverfeldt D, Reichardt W, Follo M, Albers J, Frew IJ. ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. JCI Insight. 2022 Dec 22;7(24):e156087. doi: 10.1172/jci.insight.156087. PMID: 36413415; PMCID: PMC9869969.
Hoefflin R, Harlander S, Abhari BA, Peighambari A, Adlesic M, Seidel P, Zodel K, Haug S, Göcmen B, Li Y, Lahrmann B, Grabe N, Heide D, Boerries M, Köttgen A, Heikenwalder M, Frew. Therapeutic Effects of Inhibition of Sphingosine-1-Phosphate Signaling in HIF-2α Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Sep 25;13(19):4801. doi: 10.3390/cancers13194801.
Contact
